Skip to main content
. Author manuscript; available in PMC: 2012 May 18.
Published in final edited form as: Circulation. 2010 Sep 14;122(11 Suppl):S179–S184. doi: 10.1161/CIRCULATIONAHA.109.928242

Figure 4.

Figure 4

Expression of Beclin-1 and LC3B-II with CAPS-delayed treatment. Samples were obtained from remote, normally perfused myocardium at end-reperfusion, 3.25hours following CAPS administration. Top panel: Original immunoblots. Bottom panel: Immunoreactivity of Beclin-1 and LC3B-II, corrected for GAPDH expression and normalized to control values (mean ± SEM).